Therapy Detail

Therapy Name Pemetrexed
Therapy Description

Alimta (pemetrexed) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pemetrexed Alimta LY231514 Chemotherapy - Antimetabolite 10 Alimta (pemetrexed) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03137771 Phase II Docetaxel Pemetrexed Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Recruiting
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Recruiting
NCT02264990 Phase III Pemetrexed Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Active, not recruiting
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Not yet recruiting
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Active, not recruiting
NCT02117024 Phase II Cyclophosphamide + HS-110 Pemetrexed Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Completed
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02657434 Phase III Cisplatin Atezolizumab Carboplatin Pemetrexed A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT03083808 Phase II Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Pemetrexed Phase II Trial of Continuation Therapy in Advanced NSCLC Recruiting
NCT02578680 Phase III Carboplatin Pembrolizumab Pemetrexed Cisplatin Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Active, not recruiting
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Active, not recruiting
NCT03257267 Phase III Irinotecan Gemcitabine Vinorelbine Pemetrexed Cemiplimab Topotecan Study of REGN2810 in Adults With Cervical Cancer Recruiting
NCT01553942 Phase II Afatinib Cisplatin Pemetrexed Afatinib With CT and RT for EGFR-Mutant NSCLC Recruiting
NCT02419495 Phase I Cyclophosphamide Pemetrexed Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin Selinexor in Combination With Standard Chemotherapy Recruiting
NCT02134912 Phase II Crizotinib + Pemetrexed Pemetrexed S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Terminated
NCT01664754 Phase I Pemetrexed Carboplatin Exemestane Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Completed
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Active, not recruiting
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Recruiting
NCT01646125 Docetaxel Luminespib Pemetrexed An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated
NCT03737994 Phase II Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Crizotinib Carboplatin + Pemetrexed Lorlatinib Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) Recruiting
NCT01708993 Phase II Docetaxel Pemetrexed Pemetrexed + Reolysin Docetaxel + Reolysin Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed
NCT00950365 Phase II Erlotinib + Pemetrexed Pemetrexed Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Bevacizumab Carboplatin + Pemetrexed Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Active, not recruiting
NCT02322281 Phase III Pemetrexed Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting
NCT01828112 Phase III Docetaxel Pemetrexed Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting
NCT02387216 Phase II Seribantumab Pemetrexed Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Recruiting
NCT01107626 Phase III Pemetrexed Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT02220894 Phase III Pemetrexed Carboplatin + Paclitaxel Pembrolizumab Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Active, not recruiting
NCT01928160 Phase II Erlotinib + Pemetrexed Pemetrexed Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Withdrawn
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Active, not recruiting
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Carboplatin Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) Active, not recruiting